Complete blood count as a prognostic tool for NSCLC patients treated with immune checkpoint inhibitors.

• DOI: 10.1200/jco.2025.43.16_suppl.e20564
• Publication Date: 2025-05-28T18:32:01Z
• Authors: Katiane Tostes; Emanuela Lando; Tauana Christina ...; Gabriela Karam Re...; Flavio Augusto Fe...; Augusto Perazzolo...; Leticia Ferro Leal; Lidia Rebolho Ara...
• Keywords: Immune checkpoint; Complete blood count; Blood count

e20564 Background: Lung cancer accounts for 1.8 million deaths annually, making it the leading cause of cancer-related mortality, with 85% cases diagnosed as non-small cell lung (NSCLC). Immunotherapy, in particular use immune checkpoint inhibitors (ICIs), has undergone substantial advancement through employment monoclonal antibodies to regulate pivotal pathways. While ICIs have exhibited superior efficacy comparison conventional second-line chemotherapy regimens, identification reliable prognostic markers remains imperative. The study aimed investigate significance complete blood count (CBC) values NSCLC patients undergoing ICI therapy, focusing on associations clinical outcomes such overall survival (OS) and progression-free (PFS). Methods: A retrospective medical record review was conducted advanced treated at Barretos Cancer Hospital. Demographic data were collected used create Score1= (RDW X erythrocyte). primary OS PFS assessed using SPSS software. Results: cohort included 105 patients, adenocarcinoma representing predominant histological type (57.0%). Of participants, 58.0% male, 61.0% stage IV. In terms PD-L1 status, 62.9% tested positive, 79.9% these receiving anti-PD-1 therapy. Notably, only 11.0% never smokers. present revealed significant between CBC components measured post-cycle 3 (PC3) therapy NSCLC. note, elevated Score 1 levels (>5.4; p =0.042) found be significantly associated reduced OS. Furthermore, an increase =0.049) a decline PFS. Conclusions: These findings underscore critical importance effective treatment ICIs. potential cost-effective biomarkers is promising, offering valuable tool refine strategies improve patient outcomes.